Jung AY, et al. - Researchers used data from 2,223 postmenopausal women with nonmetastatic breast cancer from the population-based Mamma Carcinoma Risk Factor Investigation (MARIE) study in order to: 1) determine pre- and postdiagnosis use of supplements in postmenopausal breast cancer survivors in Germany and 2) examine the relationships between postdiagnosis use of dietary supplements—in particular, antioxidants—and prognosis (total and breast cancer mortality, and recurrence-free survival) both overall and in women who received chemotherapy and radiation therapy. To that end, they performed multivariate Cox regression analysis. A total of 36% and 45% of the women reported pre- and postdiagnosis supplement use, respectively. Following a median follow-up time of 6.0 years after the 2009 re-interview, a total of 240 deaths (134 from breast cancer) and 200 breast cancer recurrences were documented. In postmenopausal women, worsened breast cancer prognosis was observed in relation to antioxidant use during chemotherapy or radiation therapy. Findings revealed no overall link between postdiagnosis supplement use and breast cancer prognosis. The current recommendation to possibly avoid the use of antioxidants during chemotherapy or radiation therapy was supported.